Anti-HPV16 E6-ribozyme Enhances Chemotherapeutic Drugs Sensitivity in Cervical Carcinoma Cell Line

ObjectiveTo study the effect of anti-HPV16 E6-ribozyme on chemotherapeutic drugs sensitivity in cervical carcinoma cell line in vitro and vivo. MethodsWith the method of lipofectin transfection, the anti-HPV16E6-ribozyme and empty eucaryotic expressing plasmids were transfected into CaSKi cell named as CaSKi, CaSKi-R, CaSKi-P, respectively. The sensitivity to chemotherapeutic drugs was examined by MTT colorimetric assay. Nude mice transplanted by three kinds of cervical cancer cells were randomly divided into control groups and DDP groups, respectively. The tumor growth inhibition in the nude mice were observed. Transmission electromicroscope was applied to detect apoptosis. ResultsThe inhibition rates of DDP，VCR，5-Fu，MMC to CaSKi-R cell were significantly higher than those to CaSKi or CaSKi-P cells（P<0.05）. Anti-HPV16E6-ribozyme increased the sensitivity of CaSKi-R to DDP，VCR，5-Fu，MMC in cervical carcinoma cell line. There were no dramatic changes in the inhibition rates of ADM,MTX,INF, Taxol, Ara-C, CTX in the three kinds of cells. The tumor weights in nude mice treated with DDP in CaSKi-R, in CaSKi-P and in CaSKi were (0.09±0.03)g,(0.26±0.07)g and (0.26±0.05)g(P＜0.05), and the inhibitory rates were 81.63%,62.32% and 63.38%, respectively. There were obvious ultrastructure changes related to apoptosis in CaSKi-R cells after being treated with DDP, and there weren't in CaSKi and CaSKi-P cells. Conclusion Anti-HPVE6-rivozyme increased the sensitivity of CaSKi cells to DDP ，VCR，5-Fu and MMC， in vitro and to DDP in vivo.